Zynex Osake

Zynex PEG

Delisted·23.12.2025

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Zynex (ZYXI) 25.8.2026 päivämäärällä.

PEG

0,00

Viimeksi päivitetty:

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Zynex on 2026 0,00 . PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Zynex oli 2025 0,00 . Se laskee % matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Zynex Osakeanalyysi

Mitä Zynex tekee? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Zynex osakkeesta

Eurpoolissa voit löytää PEG-suhde (Hinta-tuotto-kasvu-suhde) Zynex:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

PEG-suhde korjaa P/E-suhteen odotetulla tuottojen kasvuvauhdilla. PEG alle 1 voi viitata osakkeeseen, joka on aliarvostettu suhteessa sen kasvupotentiaaliin.

PEG = P/E-suhde / Odotettu vuosittainen EPS-kasvuprosentti

Arvioidakseen PEG-suhde (Hinta-tuotto-kasvu-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja PEG-suhde (Hinta-tuotto-kasvu-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata PEG-suhde (Hinta-tuotto-kasvu-suhde):n Zynex alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Zynex

Kaikki tunnusluvut — Zynex